Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Overweight

Overweight

46 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Overweight

140 trials tracked for Overweight: 42 in phase 3 or 4 and 24 with published results. The most-cited published study has 6076 citations.

140Trials tracked
42Phase 3 & 4
0Recruiting
24With published results
Phase distribution
Phase 4 11 Phase 3 31 Phase 2 15 Phase 1 5 Other / NA 78
  1. Phase 4 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Completed · 6,076 cited
  2. Phase 3 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity Completed · 4,608 cited
  3. Phase 3 Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity Completed · 1,327 cited
  4. Phase 3 STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity Completed · 1,310 cited
  5. Phase 3 Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program Completed · 1,035 cited
  6. Phase 3 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity Completed · 885 cited
Show 44 more trials
  1. Phase 3 Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Completed · 795 cited
  2. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight Completed · 707 cited
  3. Phase 3 A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity Completed · 655 cited
  4. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities Completed · 451 cited
  5. Phase 3 Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) Completed · 383 cited
  6. Phase 3 Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach Completed · 266 cited
  7. Phase 4 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed · 264 cited
  8. Phase 4 Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes Completed · 246 cited
  9. Phase 3 Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. Completed · 118 cited
  10. Phase 3 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed · 118 cited
  11. Phase 3 A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) Completed · 115 cited
  12. Phase 3 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range Completed · 75 cited
  13. Phase 3 Targeting Inflammation Using Salsalate in CardioVascular Disease Completed · 61 cited
  14. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss Completed · 24 cited
  15. Phase 3 Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management Completed · 13 cited
  16. Phase 3 A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program Completed · 6 cited
  17. Phase 4 Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc Completed · 5 cited
  18. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Completed · 2 cited
  19. Phase 4 Mechanisms of Weight Loss With SGLT2 Inhibition Completed
  20. Phase 4 Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers Completed
  21. Phase 4 Angiotensin II Blockade and Inflammation in Obesity Completed
  22. Phase 4 Effect of Calcium + Vitamin D Supplementation on Weight Management in Very-low Calcium Consumers Completed
  23. Phase 4 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women Completed
  24. Phase 4 Effect of Orlistat in Body Composition Completed
  25. Phase 4 Litramine in Weight Maintenance Completed
  26. Phase 3 Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function Completed
  27. Phase 3 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range Completed
  28. Phase 3 Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension Completed
  29. Phase 3 A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program Completed
  30. Phase 3 Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women Completed
  31. Phase 3 A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Completed
  32. Phase 3 Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects Completed
  33. Phase 3 A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects Completed
  34. Phase 3 Efficacy and Safety of IQP-VV-102 in Weight Management Completed
  35. Phase 3 Efficacy and Safety of Zenoctil in Reducing Body Weight Completed
  36. Phase 3 A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes Completed
  37. Phase 2 Trial of Leptin Administration After Roux-en-Y Gastric Bypass Completed
  38. Phase 2 A Study of LY3437943 in Participants Who Have Obesity or Are Overweight Completed
  39. Phase 2 Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth Completed
  40. Phase 2 A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults Completed
  41. Phase 2 A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects Completed
  42. Phase 2 Inflammation, Polyphenols, and Genetics Completed
  43. Phase 2 A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects. Completed
  44. Phase 2 Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. Completed

Showing the 50 most-cited and recently-updated of 140 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Overweight: what the trials found

Semaglutide demonstrated significant weight reduction across multiple trials, with percentage changes ranging from -12.2% to -15.8% compared to placebo (p<0.0001) [1, 2, 3]. In these studies, a high proportion of participants achieved a weight loss of at least 5% [1, 2, 3]. Additionally, semaglutide was associated with improvements in waist-height ratio 3 and physical function scores related to quality of life 2.

Orlistat was shown to significantly reduce body weight by -5.96% compared to -3.91% at week 24 (p=0.026) and decrease abdominal visceral adipose tissue (VAT) mass at both 12 and 24 weeks 20.

Calcium carbonate was associated with a statistically significant reduction in fat percentage (p=0.031) and reductions in body fat mass, body lean mass, and visceral fat mass (p=0.038), though the change in total body weight did not reach statistical significance 21.

Semaglutide was associated with a significant reduction in the risk of major cardiovascular events (CV death, non-fatal MI, or non-fatal stroke) compared to placebo (p<0.0001) 22.

Recent results — preliminary, needs further review

  • Orforglipron is currently being evaluated in Phase 1 trials for weight management 4.
  • The MOVE!+UP intervention showed no statistically significant difference in weight change at 6 or 12 months (p=0.50, p=0.49) 5.
  • Core Behavioral Weight Loss (BWL) interventions showed significant results for meeting daily weighing goals (p=0.03) and staying under red food limits (p=0.02), but no significant difference in meeting active minute goals (p=1.00) 8.
  • The HARMONY trial reported changes in dietary risk assessment scores and Veggie Meter scores, as well as a change in waist-to-hip ratio 7.

For the clinician treating this condition

  • Semaglutide is an effective intervention for significant weight reduction (12.2% to 15.8%), improved waist-height ratios, and reduced cardiovascular risk [1, 2, 3, 22].
  • Orlistat provides statistically significant reductions in both total body weight and abdominal visceral adipose tissue mass 20.
  • Calcium carbonate may contribute to a reduction in fat percentage and visceral fat mass despite non-significant changes in total body weight 21.

AI synthesis of 9 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Elecoglipron results in 40.4% to 88.8% of patients reaching at least 5% weight loss
Diabetes & Endocrinology RCT
Elecoglipron results in 40.4% to 88.8% of patients reaching at least 5% weight loss Trial shows weight loss in adults with obesity using elecoglipron
This Phase 2 randomized controlled trial evaluated elecoglipron in 310 adults with obesity or overweight and a weight-related condition. Par…
A new clinical trial shows that the medication elecoglipron helps people with obesity lose a significant amount of body weight.
Jun 20, 2026
Aerobic exercise and high-intensity interval training reduce fat mass in women with overweight or obesity
Diabetes & Endocrinology Sys. Review
Aerobic exercise and high-intensity interval training reduce fat mass in women with overweight or obesity Vigorous aerobic exercise shows best results for reducing body fat
This systematic review and network meta-analysis of randomized controlled trials evaluated structured exercise interventions for body compos…
Women with overweight or obesity may see the greatest reductions in body fat and BMI through vigorous aerobic exercise programs.
Jun 18, 2026
Intensive lifestyle intervention protocol designed to identify predictors of weight loss success
Primary Care & Family Medicine RCT
Intensive lifestyle intervention protocol designed to identify predictors of weight loss success New plan seeks personalized ways to manage weight and obesity
This randomized controlled trial protocol describes a study involving 600 individuals with varying BMI levels. The study aims to evaluate an…
A new trial design aims to find specific signs that predict if intensive lifestyle changes will work for people with weight concerns.
medRxiv Jun 9, 2026
Oral white kidney bean extract reduces weight by 1.62 kg in adults with overweight or obesity compared to placebo
Diabetes & Endocrinology Meta-analysis
Oral white kidney bean extract reduces weight by 1.62 kg in adults with overweight or obesity compared to placebo White kidney bean extract helps adults with overweight lose weight in this review
This systematic review and meta-analysis evaluated oral white kidney bean extract for weight management in adults with overweight or obesity…
A review of 543 adults found that taking white kidney bean extract led to weight loss and reduced body fat compared to a placebo.
Jun 5, 2026
Modulating endogenous PYY expression offers a theoretical basis for individualized obesity management strategies
Nutrition & Obesity Medicine Sys. Review
Modulating endogenous PYY expression offers a theoretical basis for individualized obesity management strategies Ways to boost body's fullness hormone for weight control
This narrative review discusses modulating endogenous PYY expression via dietary interventions, bariatric surgery, exercise therapy, and phy…
This review explores how diet, surgery, and exercise can raise PYY levels, helping people feel fuller and manage weight more effectively.
Frontiers Jun 4, 2026
Tirzepatide improves waist-to-height ratio in adults with obesity or overweight
Diabetes & Endocrinology RCT
Tirzepatide improves waist-to-height ratio in adults with obesity or overweight Tirzepatide improves waist-to-height ratio in obesity and prediabetes
A post-hoc analysis of a Phase 3 RCT found that tirzepatide (10/15 mg) improved waist-to-height ratio (WHtR) in adults with obesity or overw…
A new analysis finds tirzepatide helps more people with obesity achieve a healthier waist-to-height ratio, a key measure of belly fat risk.
Jun 1, 2026
Systematic review shows pre-pregnancy weight loss interventions do not significantly reduce gestational diabetes mellitus risk in women with overweight or obesity
Diabetes & Endocrinology Meta-analysis
Systematic review shows pre-pregnancy weight loss interventions do not significantly reduce gestational diabetes mellitus risk in women with overweight or obesity Pre-pregnancy weight loss does not cut diabetes risk
A meta-analysis of 1632 adult women found that pre-pregnancy weight loss interventions did not significantly lower gestational diabetes risk…
A review of 1,632 women found that pre-pregnancy weight loss did not significantly lower the risk of gestational diabetes, even though it di…
Jun 1, 2026
Wearable activity tracker adherence associated with reduced body fat in a 12-month randomized trial
Primary Care & Family Medicine RCT
Wearable activity tracker adherence associated with reduced body fat in a 12-month randomized trial Wearable tracker use linked to lower body fat in overweight adults
This randomized controlled trial examined 502 participants with a mean age of 45 years and mean BMI of 33.7 kg/m. The study assessed associa…
Wearable activity trackers linked to lower body fat in overweight adults after one year. This trial examined how consistent movement goals a…
May 27, 2026
Digital toolkit for weight management failed to improve weight loss maintenance in European adults
Primary Care & Family Medicine RCT
Digital toolkit for weight management failed to improve weight loss maintenance in European adults Digital weight loss tools failed to help most people keep off the pounds in this trial
This 2x2 factorial randomized controlled trial evaluated a digital toolkit targeting self-regulation or motivation in 1627 European adults w…
A new trial found that digital tools for weight management did not help adults keep off weight compared to standard advice and tracking.
May 21, 2026
Systematic review and meta-analysis of metformin for pediatric overweight and obesity shows modest BMI reduction
Diabetes & Endocrinology Meta-analysis
Systematic review and meta-analysis of metformin for pediatric overweight and obesity shows modest BMI reduction Metformin shows promise for weight management in children with overweight or obesity
This systematic review and meta-analysis evaluated metformin versus placebo in children with overweight or obesity across 19 original studie…
A meta-analysis of 19 studies suggests metformin may help lower BMI and weight in children with overweight or obesity compared to placebo.
May 19, 2026
Meta-analysis shows intermittent fasting lowers BMI and fasting glucose in women with overweight or obesity
Psychiatry Meta-analysis
Meta-analysis shows intermittent fasting lowers BMI and fasting glucose in women with overweight or obesity Intermittent Fasting Works for Weight Loss But Has a Catch
This meta-analysis pooled data from 1287 participants to evaluate intermittent fasting in women with overweight or obesity. The analysis fou…
For women struggling with weight, intermittent fasting twice a week may lower body mass index and blood sugar, but don't expect it to fix yo…
Frontiers May 15, 2026
Review of tart cherry effects in overweight and obesity reports inconsistent metabolic findings
Nutrition & Obesity Medicine Sys. Review
Review of tart cherry effects in overweight and obesity reports inconsistent metabolic findings Tart Cherries Show Promise for Blood Pressure in Overweight Adults
This narrative review synthesizes evidence on tart cherry products for overweight and obese individuals. It suggests potential benefits for …
Tart cherries could help lower blood pressure and fight inflammation in overweight adults, but don't expect them to melt away pounds just ye…
Frontiers May 15, 2026

Questions about Overweight

Did extending sleep duration change insulin sensitivity in people with overweight?

No, extending sleep by about 1 hour per night for 6 weeks did not change insulin sensitivity in people with overweight or obesity who were short sleepers.

Full answer →
Do wholegrain rye diets help with weight loss in overweight adults?

Wholegrain rye diets do not lead to significantly more weight loss than refined wheat diets in overweight adults, but they improve metabolic markers like inflammation and gut health.

Full answer →
Do stand-alone digital lifestyle interventions improve weight for adults with overweight?

Yes, stand-alone digital lifestyle interventions (fully automated apps or websites) lead to modest weight loss and improved dietary habits in adults with overweight or obesity, based on a 2026 meta-analysis.

Full answer →
How does tirzepatide compare to semaglutide for weight reduction in adults without diabetes?

Tirzepatide leads to greater weight loss than semaglutide in adults without diabetes, based on network meta-analyses and cohort studies.

Full answer →

All Overweight Articles